Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05020860 · ClinicalTrials.gov registry record · Phase 2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
A Phase 2 study of Breast Cancer and Triple Negative Breast Cancer, sponsored by Baylor Breast Care Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 185
- Enrollment target
- 2
- Study locations
NCT05020860 is a Phase 2 study of Breast Cancer and Triple Negative Breast Cancer that is actively recruiting participants, run by Baylor Breast Care Center. The registered enrollment target is 185 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05020860, a Phase 2 study of Breast Cancer and Triple Negative Breast Cancer, is actively recruiting participants, sponsored by Baylor Breast Care Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 185 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to learn whether clinical response (the amount a tumor shrinks based on imaging or tumor measurements obtained by physical exam) predicts pathologic response (the amount of tumor remaining when surgery is performed) in participants with breast cancer who are receiving chemotherapy prior to surgery.
Conditions Studied
Interventions
- DRUG Trastuzumab
- DRUG Carboplatin
- DRUG Doxorubicin
- DRUG Paclitaxel
- DRUG Pertuzumab
Study Locations (2)
Texas
- Harris Health System - Smith Clinic - Houston
- O'Quinn Medical Tower - McNair Campus - Dan L Duncan Comprehensive Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2023-04-18 |
| Est. Completion | 2029-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05020860
The ClinicalTrials.gov registry entry for NCT05020860 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Baylor Breast Care Center, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Trastuzumab is the first listed.
NCT05020860 reports 2 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT05020860 about?
NCT05020860 is a clinical study titled "Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer". The purpose of this study is to learn whether clinical response (the amount a tumor shrinks based on imaging or tumor measurements obtained by physical exam) predicts pathologic response (the amount of tumor remaining when surgery is performed) in participants with breast cancer who are receiving ch...
What is the current status of trial NCT05020860?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 185 participants. The study started on 2023-04-18. Estimated completion is 2029-11.
What conditions does trial NCT05020860 study?
This clinical trial studies the following conditions: Breast Cancer, Triple Negative Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Female, Breast Neoplasm.
What interventions are being tested in trial NCT05020860?
The interventions under investigation include: Trastuzumab (DRUG), Carboplatin (DRUG), Doxorubicin (DRUG), Paclitaxel (DRUG), Pertuzumab (DRUG).
Who is sponsoring clinical trial NCT05020860?
This trial is sponsored by Baylor Breast Care Center, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05020860 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.